Corporate Banner
Satellite Banner
RNAi
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

BioAlliance Pharma’s Sitavig® Receives Market Authorization in the US

Published: Tuesday, April 16, 2013
Last Updated: Tuesday, April 16, 2013
Bookmark and Share
Authorization from the U.S. FDA for Sitavig® in the treatment of recurring Herpes labialis, marking the successful conclusion to the assessment procedure carried out by the American authorities.

After Loramyc ®, registered in 26 countries including the United States, BioAlliance Pharma for the second time has successfully passed the FDA review. The registration of Sitavig, developed internally, shows once again the teams’ capacity and expertise.

Based on proprietary Lauriad® technology, Sitavig® comes in the form of a mucoadhesive tablet which the patient places on the gum and which delivers a high concentration of acyclovir directly to the lip, the site of the cold sore infection. In a phase III international study conducted on 775 patients, Sitavig® demonstrated a high level of efficacy in terms of healing time with one single tablet containing 50mg of acyclovir and an excellent tolerance profile.

In addition to its efficacy, Sitavig® offers a unique unobtrusive and simple formulation with a single application for the episode’s entire duration, representing major advantages for patients suffering from recurrent herpes sores.

“Herpes labialis is an infection that affects a very large number of patients around the world and for which there is a real need for effective treatment with appropriate presentation. We participated in the phase III clinical trial in our center and were able to test the benefits of Sitavig®. We are very pleased with the outcome of this development which will allow patients, once the product is on the market, to have a drug that meets their needs," says Professor Stephen Keith Tyring of the Dermatology Department at the University of Texas Health Sciences Center in Houston.

Herpes labialis is an extremely widespread condition. Its estimated annual prevalence is 15% of the adult population1, namely some 40 million people in the United States with more than 100 million episodes of Herpes labialis annually, representing a significant potential market of hundreds of millions of dollars.

Sitavig®, the second drug of BioAlliance’s 'Specialty Products' portfolio, is intended to be marketed via international partnership agreements and to generate significant income for the company. Obtaining the MA will allow the company to accelerate discussions with potential partners for marketing in the United States.

“Drug approval in the United States represents for all laboratories, whether large or small, both a challenge and a major success once it has been obtained since the process is so complex and significant levels of competence and expertise are required. This MA demonstrates once more the ability of BioAlliance teams to successfully complete the development and registration of a drug with international agencies such as those in Europe and the United States, and also strengthens its unique positioning within the current landscape of French Biotechs through its second drug registered for the major markets and three products in advanced clinical phase. This is a key step in creating company value for our shareholders and should allow us to generate revenue, thereby fully participating in the growth and success of BioAlliance,” states Judith Greciet, CEO of BioAlliance Pharma.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More than 4,900+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

BioAlliance Pharma Announces Shareholders’ Meeting and Appointment of Independant Board Members
As a result of the shareholder’s meeting, Dr Russell Greig and Danièle Guyot-Caparros have been appointed as independent Board Members.
Monday, July 01, 2013
Scientific News
Researchers Develop Software That Could Facilitate Drug Development
AptaTRACE can identify aptamers, potentially speed drug advancement.
Gene Therapy for Metabolic Liver Diseases
Researchers have tested gene therapy in pigs from hereditary tyrosinemia type 1, with corrected liver cells being transplanted into the diseased liver.
Gene Terapy for Muscle Wasting Developed
New gene therapy could save millions of people suffering from muscle wasting disease.
Testing Nanoparticle Drug Delivery in Dogs
Scientists have tested a nanoparticle drug delivery against bone cancer in dogs with promising results.
Fighting Cancer Through Protein Pathways
Researchers have found a new drug target within a protein production pathway critical to regulating growth and proliferation of cells.
Triple-Action Therapy Patch Shows Promise
Patch that delivers drug, gene, and light-based therapy to tumor sites shows promising results in mice.
Cancer Gene-Drug Combinations Ripe for Precision Medicine
The study aims to expand the number of cancer gene mutations that can be paired with a precision therapy.
Exploiting Malaria’s Achilles’ Heel
Researchers have uncovered an Achilles' heel in malaria's anti-drug treatment arsenal that could lead to a disease cure.
Targeting BRAF Mutations in Thyroid Cancer
Treating metastatic thyroid cancer patients harboring a BRAF mutation with vemurafenib showed anti-tumor activity in a third of patients.
Colon Cancer Blocked in Mice
Case Western Reserve University Researchers block common type of colon cancer tumour in mice, laying groundwork for human clinical trial.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,900+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!